argenx NV ADR (ARGX)vsRoyalty Pharma Plc (RPRX)
ARGX
argenx NV ADR
$783.50
+0.23%
HEALTHCARE · Cap: $48.96B
RPRX
Royalty Pharma Plc
$49.47
-1.24%
HEALTHCARE · Cap: $29.33B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 78% more annual revenue ($4.24B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 30.5%. ARGX appears more attractively valued with a PEG of 1.25. ARGX earns a higher WallStSmart Score of 61/100 (C+).
ARGX
Buy61
out of 100
Grade: C+
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.4%
Fair Value
$2106.55
Current Price
$783.50
$1323.05 discount
Margin of Safety
-11.3%
Fair Value
$39.76
Current Price
$49.47
$9.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Strong operational efficiency at 27.4%
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.6x book value
Earnings declined 31.9%
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while RPRX is a value play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.39 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
RPRX generates stronger free cash flow (827M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (61/100 vs 57/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?